scholarly journals The sociodemographic and clinical profile of patients with major depressive disorder receiving SSRIs as first-line antidepressant treatment in European countries

Author(s):  
Gernot Fugger ◽  
Lucie Bartova ◽  
Chiara Fabbri ◽  
Giuseppe Fanelli ◽  
Markus Dold ◽  
...  

Abstract Introduction Due to favorable antidepressant (AD) efficacy and tolerability, selective-serotonin reuptake inhibitors (SSRIs) are consistently recommended as substances of first choice for the treatment of major depressive disorder (MDD) in international guidelines. However, little is known about the real-world clinical correlates of patients primarily prescribed SSRIs in contrast to those receiving alternative first-line ADs. Methods These secondary analyses are based on a naturalistic, multinational cross-sectional study conducted by the European Group for the Study of Resistant Depression at ten research sites. We compared the socio-demographic and clinical characteristics of 1410 patients with primary MDD, who were either prescribed SSRIs or alternative substances as first-line AD treatment, using chi-squared tests, analyses of covariance, and logistic regression analyses. Results SSRIs were prescribed in 52.1% of MDD patients who showed lower odds for unemployment, current severity of depressive symptoms, melancholic features, suicidality, as well as current inpatient treatment compared to patients receiving alternative first-line ADs. Furthermore, patients prescribed SSRIs less likely received add-on therapies including AD combination and augmentation with antipsychotics, and exhibited a trend towards higher response rates. Conclusion A more favorable socio-demographic and clinical profile associated with SSRIs in contrast to alternative first-line ADs may have guided European psychiatrists’ treatment choice for SSRIs, rather than any relevant pharmacological differences in mechanisms of action of the investigated ADs. Our results must be cautiously interpreted in light of predictable biases resulting from the open treatment selection, the possible allocation of less severely ill patients to SSRIs as well as the cross-sectional study design that does not allow to ascertain any causal conclusions.

2017 ◽  
Vol 52 ◽  
pp. 258-264 ◽  
Author(s):  
Janette Z. Canales ◽  
Juliana T. Fiquer ◽  
Rodolfo N. Campos ◽  
Márcio Gerhardt Soeiro-de-Souza ◽  
Ricardo Alberto Moreno

2012 ◽  
Vol 130 (3) ◽  
pp. 167-172 ◽  
Author(s):  
Shahnaz Khaleghipour ◽  
Mohsen Masjedi ◽  
Hassan Ahade ◽  
Meersalahodin Enayate ◽  
Gholamreza Pasha ◽  
...  

CONTEXT AND OBJECTIVE: The pineal gland is an adaptive organ that precisely regulates the biological rhythms of melatonin brain hemostasis. Variation in the regulation of melatonin rhythms is a likely cause of depressive disorder. The purpose of this study was to measure serum melatonin levels in patients with major depressive disorder (MDD) and normal control subjects. DESIGN AND SETTING: Analytical cross-sectional study at the industrial medical unit of the Iron Smelting Company of Isfahan, Iran. METHODS: The morning and nocturnal serum melatonin levels of patients and controls were measured using the enzyme-linked immunosorbent assay (ELISA) method. All data were assessed using variance analysis. RESULTS: The morning and nocturnal serum melatonin levels of depressed and healthy subjects differed (P < 0.05). The nocturnal serum melatonin levels of depressed women were lower than those of depressed men (P < 0.05). CONCLUSIONS: The findings of this study showed that the nocturnal serum melatonin levels in the depressed patients were lower than in the controls. Thus, the peak melatonin phase in the depressed patients was reached with delay. CLINICAL TRIAL REGISTRATION NUMBER: NCT01357083


Sign in / Sign up

Export Citation Format

Share Document